5-氨基乙酰丙酸对新型冠状病毒奥密克戎变异株的体外抗病毒疗效
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro.
作者信息
Ngwe Tun Mya Myat, Sakura Takaya, Sakurai Yasuteru, Kurosaki Yohei, Inaoka Daniel Ken, Shioda Norifumi, Smith Chris, Yasuda Jiro, Morita Kouichi, Kita Kiyoshi
机构信息
Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Department of Molecular Infection Dynamics, Shionogi Global Infectious Diseases Division, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
出版信息
Trop Med Health. 2022 Apr 27;50(1):30. doi: 10.1186/s41182-022-00422-7.
The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) has demonstrated antiviral activity in Wuhan, Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 infections in vitro. In this study, we report antiviral activity of 5-ALA, 5-ALA with SFC led to IC of 329 and 765/191, respectively after infection with Omicron variant of SARS-CoV-2 in vitro. Our finding suggests that 5-ALA could be used as antiviral drug candidate to treat Omicron variant infected patients.
2019年冠状病毒病（COVID-19）大流行继续对全球健康构成威胁。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种（B.1.1.529）已在全球迅速传播，并在许多国家占据主导地位。天然5-氨基乙酰丙酸（5-ALA）与柠檬酸亚铁钠（SFC）在体外对SARS-CoV-2感染的武汉变种、阿尔法变种、贝塔变种、伽马变种和德尔塔变种已显示出抗病毒活性。在本研究中，我们报告了5-ALA的抗病毒活性，在体外感染SARS-CoV-2奥密克戎变种后，5-ALA与SFC分别导致半数抑制浓度（IC）为329和765/191。我们的研究结果表明，5-ALA可作为治疗奥密克戎变种感染患者的抗病毒候选药物。
Zotero 插件